CymaBay Therapeutics (CBAY) – Major News
-
CymaBay Therapeutics (CBAY) Misses Q4 EPS by 4c
-
Gilead Sciences (GILD) to Acquire CymaBay Therapeutics (CBAY) for $32.50 Per Share, $4.3 Billion
-
CymaBay Therapeutics (CBAY) Misses Q3 EPS by 3c
-
CymaBay Therapeutics (CBAY) Tops Q2 EPS by 19c
-
CymaBay Therapeutics (CBAY) Misses Q1 EPS by 20c
-
CymaBay Therapeutics (CBAY) Reports In-Line Q4 EPS
-
CymaBay Therapeutics (CBAY) Tops Q3 EPS by 2c
-
CymaBay Therapeutics (CBAY) Misses Q2 EPS by 2c
-
CymaBay Therapeutics (CBAY) Announces FDA Lifts All Clinical Holds on Seladelpar
-
CymaBay Therapeutics (CBAY) Tops Q2 EPS by 2c
-
CymaBay Therapeutics (CBAY) Tops Q4 EPS by 8c, Beats on Revenues
-
CymaBay Therapeutics (CBAY) Misses Q3 EPS by 2c
-
CymaBay Therapeutics (CBAY) Enters Exclusive Licensing Deal with Kowa Pharmaceuticals for Arhalofenate in the U.S.
-
CymaBay Therapeutics (CBAY) Tops Q3 EPS by 6c
-
CymaBay Therapeutics (CBAY) Tops Q2 EPS by 33c
-
CymaBay Therapeutics (CBAY) Misses Q4 EPS by 40c
-
CymaBay Therapeutics (CBAY) Tops Q3 EPS by 3c
Back to CBAY Stock Lookup